405 related articles for article (PubMed ID: 33312159)
1. GDF-15 as a Weight Watcher for Diabetic and Non-Diabetic People Treated With Metformin.
Ouyang J; Isnard S; Lin J; Fombuena B; Peng X; Chen Y; Routy JP
Front Endocrinol (Lausanne); 2020; 11():581839. PubMed ID: 33312159
[TBL] [Abstract][Full Text] [Related]
2. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice.
Frikke-Schmidt H; Hultman K; Galaske JW; Jørgensen SB; Myers MG; Seeley RJ
Mol Metab; 2019 Mar; 21():13-21. PubMed ID: 30685336
[TBL] [Abstract][Full Text] [Related]
3. The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance.
Klein AB; Nicolaisen TS; Johann K; Fritzen AM; Mathiesen CV; Gil C; Pilmark NS; Karstoft K; Blond MB; Quist JS; Seeley RJ; Færch K; Lund J; Kleinert M; Clemmensen C
Cell Rep; 2022 Aug; 40(8):111258. PubMed ID: 36001956
[TBL] [Abstract][Full Text] [Related]
4. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss.
Day EA; Ford RJ; Smith BK; Mohammadi-Shemirani P; Morrow MR; Gutgesell RM; Lu R; Raphenya AR; Kabiri M; McArthur AG; McInnes N; Hess S; Paré G; Gerstein HC; Steinberg GR
Nat Metab; 2019 Dec; 1(12):1202-1208. PubMed ID: 32694673
[TBL] [Abstract][Full Text] [Related]
5. GDF15 mediates the effects of metformin on body weight and energy balance.
Coll AP; Chen M; Taskar P; Rimmington D; Patel S; Tadross JA; Cimino I; Yang M; Welsh P; Virtue S; Goldspink DA; Miedzybrodzka EL; Konopka AR; Esponda RR; Huang JT; Tung YCL; Rodriguez-Cuenca S; Tomaz RA; Harding HP; Melvin A; Yeo GSH; Preiss D; Vidal-Puig A; Vallier L; Nair KS; Wareham NJ; Ron D; Gribble FM; Reimann F; Sattar N; Savage DB; Allan BB; O'Rahilly S
Nature; 2020 Feb; 578(7795):444-448. PubMed ID: 31875646
[TBL] [Abstract][Full Text] [Related]
6. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.
Mullican SE; Lin-Schmidt X; Chin CN; Chavez JA; Furman JL; Armstrong AA; Beck SC; South VJ; Dinh TQ; Cash-Mason TD; Cavanaugh CR; Nelson S; Huang C; Hunter MJ; Rangwala SM
Nat Med; 2017 Oct; 23(10):1150-1157. PubMed ID: 28846097
[TBL] [Abstract][Full Text] [Related]
7. Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure.
Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Nadwa EH; Albogami SM; Alorabi M; Saad HM; Batiha GE
J Diabetes; 2022 Dec; 14(12):806-814. PubMed ID: 36444166
[TBL] [Abstract][Full Text] [Related]
8. GDF-15, a future therapeutic target of glucolipid metabolic disorders and cardiovascular disease.
Xiao QA; He Q; Zeng J; Xia X
Biomed Pharmacother; 2022 Feb; 146():112582. PubMed ID: 34959119
[TBL] [Abstract][Full Text] [Related]
9. Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: A nested, case-control study.
Natali A; Nesti L; Venturi E; Shore AC; Khan F; Gooding K; Gates PE; Looker HC; Dove F; Goncalves I; Persson M; Nilsson J;
Diabetes Obes Metab; 2019 Feb; 21(2):412-416. PubMed ID: 30178545
[TBL] [Abstract][Full Text] [Related]
10. The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study.
Au Yeung SL; Luo S; Schooling CM
Diabetologia; 2019 Sep; 62(9):1638-1646. PubMed ID: 31161347
[TBL] [Abstract][Full Text] [Related]
11. Upregulated GDF-15 expression facilitates pancreatic ductal adenocarcinoma progression through orphan receptor GFRAL.
Zhao Z; Zhang J; Yin L; Yang J; Zheng Y; Zhang M; Ni B; Wang H
Aging (Albany NY); 2020 Nov; 12(22):22564-22581. PubMed ID: 33201838
[TBL] [Abstract][Full Text] [Related]
12. Metformin: Mechanisms in Human Obesity and Weight Loss.
Yerevanian A; Soukas AA
Curr Obes Rep; 2019 Jun; 8(2):156-164. PubMed ID: 30874963
[TBL] [Abstract][Full Text] [Related]
13. The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1.
Unsicker K; Spittau B; Krieglstein K
Cytokine Growth Factor Rev; 2013 Aug; 24(4):373-84. PubMed ID: 23787157
[TBL] [Abstract][Full Text] [Related]
14. Diabetes prevention.
Brousseau VJ
N Engl J Med; 2002 Jun; 346(23):1829-30; author reply 1829-30. PubMed ID: 12051267
[No Abstract] [Full Text] [Related]
15. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL.
Emmerson PJ; Wang F; Du Y; Liu Q; Pickard RT; Gonciarz MD; Coskun T; Hamang MJ; Sindelar DK; Ballman KK; Foltz LA; Muppidi A; Alsina-Fernandez J; Barnard GC; Tang JX; Liu X; Mao X; Siegel R; Sloan JH; Mitchell PJ; Zhang BB; Gimeno RE; Shan B; Wu X
Nat Med; 2017 Oct; 23(10):1215-1219. PubMed ID: 28846098
[TBL] [Abstract][Full Text] [Related]
16. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis.
Björkhem-Bergman L; Asplund AB; Lindh JD
J Psychopharmacol; 2011 Mar; 25(3):299-305. PubMed ID: 20080925
[TBL] [Abstract][Full Text] [Related]
17. Effects of metformin on weight loss: potential mechanisms.
Malin SK; Kashyap SR
Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):323-9. PubMed ID: 25105996
[TBL] [Abstract][Full Text] [Related]
18. Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malmö Diet and Cancer-Cardiovascular Cohort.
Bao X; Borné Y; Muhammad IF; Nilsson J; Lind L; Melander O; Niu K; Orho-Melander M; Engström G
Diabetologia; 2019 Jan; 62(1):78-86. PubMed ID: 30350239
[TBL] [Abstract][Full Text] [Related]
19. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand.
Yang L; Chang CC; Sun Z; Madsen D; Zhu H; Padkjær SB; Wu X; Huang T; Hultman K; Paulsen SJ; Wang J; Bugge A; Frantzen JB; Nørgaard P; Jeppesen JF; Yang Z; Secher A; Chen H; Li X; John LM; Shan B; He Z; Gao X; Su J; Hansen KT; Yang W; Jørgensen SB
Nat Med; 2017 Oct; 23(10):1158-1166. PubMed ID: 28846099
[TBL] [Abstract][Full Text] [Related]
20. A 24-month metformin treatment study of children with obesity: Changes in circulating GDF-15 and associations with changes in body weight and visceral fat.
Carreras-Badosa G; Gómez-Vilarrubla A; Mas-Parés B; Martínez-Calcerrada JM; Xargay-Torrent S; Prats-Puig A; Puerto-Carranza E; Díaz-Roldán F; de Zegher F; Ibañez L; Bassols J; López-Bermejo A
Pediatr Obes; 2022 Feb; 17(2):e12845. PubMed ID: 34427052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
